Pharmaceutical companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Roivant Sciences leads the 50 pharmaceutical companies ranked by P/S ratio, at 3387, ahead of Dianthus Therapeutics (2352) and Protagonist Therapeutics (180). Figures as of 18 Nov 2026, 20:24 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 50
- First
- Roivant Sciences3387
- Median
- 6.9
- Combined market value
- CZK 112.71T
- Countries
- 10
- Not ranked
- 11no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/S ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Roivant SciencesROIV · Health Care | 3387 | CZK 621.5B | CZK 857.79 | 0.25% down | 90% up | ||
| 2 | Dianthus TherapeuticsDNTH · Health Care | 2352 | CZK 106.4B | CZK 1,888.63 | 2.25% down | 113% up | ||
| 3 | Protagonist TherapeuticsPTGX · Health Care | 180 | CZK 183.6B | CZK 2,812.29 | 1.55% up | 46% up | ||
| 4 | CytokineticsCYTK · Health Care | 81.7 | CZK 159.7B | CZK 1,146.46 | 0.08% down | 20% down | ||
| 5 | Rhythm PharmaceuticalsRYTM · Health Care | 43.4 | CZK 183.1B | CZK 2,640.36 | 1.93% up | 13% up | ||
| 6 | InsmedINSM · Health Care | 43.3 | CZK 583.9B | CZK 2,661.79 | 1.67% down | 40% down | ||
| 7 | BridgeBio PharmaBBIO · Health Care | 30.2 | CZK 337.1B | CZK 1,730.47 | 1.43% up | 17% up | ||
| 8 | Ligand PharmaceuticalsLGND · Health Care | 22.3 | CZK 132.6B | CZK 6,629.99 | 1.58% up | 43% up | ||
| 9 | Ascendis PharmaASND · Health Care | 22.2 | CZK 394.9B | CZK 6,020.11 | 0.07% down | 28% up | ||
| 10 | Eli LillyLLY · Health Care | 19.0 | CZK 27.46T | CZK 30,830.14 | 1.96% down | 35% up | ||
| 11 | Royalty PharmaRPRX · Health Care | 16.7 | CZK 882.7B | CZK 1,535.10 | 0.62% up | 78% up | ||
| 12 | TG TherapeuticsTGTX · Health Care | 16.2 | CZK 221.6B | CZK 1,466.12 | 5.25% up | 107% up | ||
| 13 | Mirum PharmaceuticalsMIRM · Health Care | 11.6 | CZK 134B | CZK 2,052.80 | 0.50% up | 31% up | ||
| 14 | Vertex PharmaceuticalsVRTX · Health Care | 11.4 | CZK 3.03T | CZK 11,954.35 | 0.74% up | 27% up | ||
| 15 | Axsome TherapeuticsAXSM · Health Care | 11.1 | CZK 156.8B | CZK 2,980.12 | 1.32% down | 7% down | ||
| 16 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 11.0 | CZK 165.8B | CZK 2,110.33 | 0.12% down | 126% up | ||
| 17 | Travere TherapeuticsTVTX · Health Care | 9.9 | CZK 107.7B | CZK 1,122.03 | 1.15% down | 44% up | ||
| 18 | Corcept TherapeuticsCORT · Health Care | 9.8 | CZK 165.4B | CZK 1,511.22 | 2.91% down | 8% down | ||
| 19 | Madrigal PharmaceuticalsMDGL · Health Care | 9.7 | CZK 205.7B | CZK 8,853.83 | 5.55% down | 24% down | ||
| 20 | BeOne MedicinesONC · Health Care | 8.6 | CZK 1.02T | CZK 8,967.13 | 2.32% down | 17% up | ||
| 21 | GenmabGMAB · Health Care | 8.5 | CZK 700.6B | CZK 1,136.25 | 1.56% down | 70% up | ||
| 22 | AbbVieABBV · Health Care | 8.3 | CZK 11.25T | CZK 6,366.75 | 2.12% down | 26% up | ||
| 23 | United TherapeuticsUTHR · Health Care | 7.8 | CZK 548.6B | CZK 12,880.57 | 0.73% down | 23% up | ||
| 24 | Arrowhead PharmaceuticalsARWR · Health Care | 7.4 | CZK 136.2B | CZK 963.20 | 0.86% up | 10% up | ||
| 25 | Johnson & JohnsonJNJ · Health Care | 7.0 | CZK 14.64T | CZK 6,082.64 | 1.75% down | 38% up | ||
| 26 | Regeneron PharmaceuticalsREGN · Health Care | 6.8 | CZK 2.18T | CZK 21,029.33 | 1.16% down | 36% up | ||
| 27 | Alnylam PharmaceuticalsALNY · Health Care | 5.4 | CZK 444.8B | CZK 3,320.66 | 4.48% down | 66% down | ||
| 28 | NovartisNVS · Health Care | 5.4 | CZK 6.51T | CZK 3,448.06 | 2.46% down | 25% up | ||
| 29 | AlkermesALKS · Health Care | 5.3 | CZK 173.8B | CZK 1,034.06 | 2.42% up | 58% up | ||
| 30 | Merck & CoMRK · Health Care | 5.3 | CZK 7.59T | CZK 3,077.53 | 3.37% down | 51% up | ||
| 31 | Ionis PharmaceuticalsIONS · Health Care | 4.9 | CZK 102.6B | CZK 615.88 | 2.84% up | 64% down | ||
| 32 | AstraZenecaAZN · Health Care | 4.7 | CZK 6.17T | CZK 3,978.86 | 1.73% down | 2% up | ||
| 33 | Abbott LaboratoriesABT · Health Care | 4.1 | CZK 4.04T | CZK 2,332.25 | 0.27% up | 17% down | ||
| 34 | Novo NordiskNVO · Health Care | 3.8 | CZK 3.86T | CZK 876.34 | 3.07% down | 17% down | ||
| 35 | Jazz PharmaceuticalsJAZZ · Health Care | 3.7 | CZK 351.6B | CZK 5,477.64 | 2.44% up | 37% up | ||
| 36 | ZoetisZTS · Health Care | 3.7 | CZK 779.9B | CZK 1,919.51 | 3.51% up | 29% down | ||
| 37 | BioMarin PharmaceuticalBMRN · Health Care | 3.7 | CZK 264B | CZK 1,362.83 | 4.85% up | 11% up | ||
| 38 | Dr. Reddy's LaboratoriesRDY · Health Care | 3.5 | CZK 278B | CZK 333.43 | 1.49% up | 5% up | ||
| 39 | Legend BiotechLEGN · Health Care | 3.1 | CZK 69.9B | CZK 360.53 | 0.74% up | 42% down | ||
| 40 | PTC TherapeuticsPTCT · Health Care | 2.9 | CZK 111.5B | CZK 1,334.95 | 0.44% down | 20% down | ||
| 41 | Elanco Animal HealthELAN · Health Care | 2.9 | CZK 298.6B | CZK 597.45 | 4.04% up | 20% up | ||
| 42 | Teva Pharmaceutical IndustriesTEVA · Health Care | 2.9 | CZK 1.09T | CZK 936.65 | 1.07% down | 74% up | ||
| 43 | PfizerPFE · Health Care | 2.6 | CZK 3.56T | CZK 624.77 | 1.21% down | 14% up | ||
| 44 | Bristol-Myers SquibbBMY · Health Care | 2.5 | CZK 2.72T | CZK 1,331.95 | 2.27% down | 34% up | ||
| 45 | Amneal PharmaceuticalsAMRX · Health Care | 2.5 | CZK 168.7B | CZK 484.15 | 3.20% up | 83% up | ||
| 46 | Takeda PharmaceuticalTAK · Health Care | 2.4 | CZK 1.51T | CZK 473.05 | 1.59% down | 54% up | ||
| 47 | SanofiSNY · Health Care | 2.3 | CZK 2.52T | CZK 1,048.17 | 0.73% down | 4% down | ||
| 48 | GSKGSK · Health Care | 2.3 | CZK 2.17T | CZK 1,082.49 | 1.04% down | 6% up | ||
| 49 | ViatrisVTRS · Health Care | 1.6 | CZK 520.9B | CZK 454.39 | 0.02% up | 96% up | ||
| 50 | GrifolsGRFS · Health Care | 0.7 | CZK 127.8B | CZK 187.71 | 2.09% down | 1% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2140 CZK). 11 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/S ratio?
Roivant Sciences (3387), Dianthus Therapeutics (2352) and Protagonist Therapeutics (180) are the top three of the 50 pharmaceutical companies ranked by P/S ratio as of 18 Nov 2026, 20:24 UTC.
How many pharmaceutical companies are in this ranking?
50 are ranked by P/S ratio. 11 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 50 pharmaceutical companies ranked by P/S ratio have a combined market value of CZK 112.71T as of 18 Nov 2026, 20:24 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/S ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.